Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies

SIMPLE SUMMARY: A ROR1 CAR-T cells derived from scFv of Zilovertamab with short IgG4 hinge spacer region, holds the specific cytotoxicities against a broad range of ROR1(+) solid tumors with no observed toxicity in vivo. Our results have provided preclinical evidence to further develop ROR1 CAR-T ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Boon kiat, Wan, Yuhua, Chin, Zan lynn, Deng, Linyan, Deng, Mo, Leung, Tze ming, Hua, Jian, Zhang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331269/
https://www.ncbi.nlm.nih.gov/pubmed/35892876
http://dx.doi.org/10.3390/cancers14153618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331269/
https://www.ncbi.nlm.nih.gov/pubmed/35892876
http://dx.doi.org/10.3390/cancers14153618

Ejemplares similares